Close Menu

NEW YORK (360Dx) – The Foundation for Innovative New Diagnostics (FIND) recently evaluated four rapid immunoassay-based tests that can be used for screening and triaging of patients suspected of having Ebola, revealing variable sensitivities and specificities.

In the Ebola outbreak currently raging in the Democratic Republic of Congo, an assay from Cepheid is also being used to simplify the PCR-based confirmatory testing workflow.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.